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Because favorable effects on survival were seen in randomized
trials conducted during the 1980s, adjuvant chemotherapy in colon
cancer was established as routine therapy in stage III disease in the
United States in 1990.1 Follow-up trials in the United States, Asia,
and Europe2,3 soon meant that it became recommended therapy
worldwide, not only in stage III but in stage II disease as well, if risk
factors for recurrence were present. Additional trials established the
combination of a ﬂuoropyrimidine and oxaliplatin as reference
treatment for patients with stage II disease with risk factors who are ﬁt
for therapy and for those with stage III disease.4-6 The addition of
oxaliplatin in the treatment of elderly patients has been questioned.7
Here we present arguments questioning not only the addition of
oxaliplatin in the treatment of some younger patients as well but also
the offering of adjuvant chemotherapy at all to some of these patients.
Medical care continuously develops, and as a consequence,
treatment results improve. This development has also been seen in
colon (and rectal) cancer, and the improvements actually challenge
the established beneﬁt of adjuvant chemotherapy in colon (and
rectal) cancer. We question whether the risk of recurrence is
sufﬁciently high for most patients with stage II disease, even when
risk factors are present, and for some patients with stage III disease
in the presence of high-quality, modern, multidisciplinary team
care to motivate adjuvant chemotherapy.
In colorectal cancer, there has been a marked change during
the past decades regarding surgery. It started with the total me-
sorectal excision (TME) technique for rectal cancer.8 This technique
has now spread around the world; the majority of surgeons have
learned how to operate effectively on rectal cancer, and many
centers report low local recurrence rates. Population-based data
from national quality registers also show that the local recurrence
rate can today reach approximately 5%,9,10 equaling the rates
achieved in dedicated centers.8,11-13 Surgery for colon cancer may
also be about to change, with complete mesocolic excision dis-
section and the concept of central ligation.14 These techniques have
started to spread among surgeons, and population data already
indicate that there may be an overall survival beneﬁt, in addition to
improvements reﬂecting stage migration, if colonic surgery is
performed in accordance with such procedures.15-19
Preoperative staging of colorectal cancer has also improved,
and up-to-date contrast-enhanced computed tomography of the
thorax and abdomen, completed with ultrasonography or mag-
netic resonance imaging with contrast agents in the case of
equivocal liver lesions or positron emission tomography–
computed tomography in the case of equivocal ﬁndings outside the
liver, has also resulted in fewer recurrences in those undergoing
surgery (ie, the target patients for adjuvant therapy). The scenario
has changed from fewer metachronous to more synchronous
metastases. Furthermore, although pathologists cannot reduce
recurrence risks per se, better pathologic staging results in lower
stage-speciﬁc recurrence rates, often referred to as stage migration.
The rectal cancer radiotherapy story illustrates the same kind
of problem the medical community is facing when one or several
aspects of multidisciplinary care are improved. The story is well
known from literature. The reduction in local recurrence rates seen
after preoperative radiotherapy20 was questioned when surgery was
improved (ie, when TME was introduced). The two trials then
initiated—the Dutch–Swedish TME trial and the Medical Research
Council CR07 trial in the United Kingdom,21,22 in which pre-
operative radiotherapy using the 5 3 5 Gy schedule was tested
against selective postoperative (chemo)radiotherapy—showed that
preoperative radiotherapy signiﬁcantly reduced local recurrence
rates. Actually, the relative reduction may have been slightly larger
with TME (hazard ratio, 0.38; absolute difference, 11% v 4%) than
with the older, suboptimal surgery (hazard ratio, 0.46; absolute
difference, 27% v 13%). The overall survival gain seen previously in
the Swedish Rectal Cancer Trial23 could not be reproduced; the
absolute gain in local recurrences was likely too small to show up in
the trials in which TME was used.
The gains from postoperative chemoradiotherapy in local
recurrence rates and survival24 have not been tested using TME. In
a German trial testing pre- versus postoperative chemoradiotherapy,
it was shown that preoperative chemoradiotherapy was better than
postoperative in reducing the local recurrence rate, approximately
10% after postoperative treatment versus 7% after preoperative
irradiation. The TME technique was used for most patients in the
trial, but no difference in survival could be seen even after long-term
follow-up.25
On the basis of this knowledge, there is an ongoing debate
over whether radiotherapy is needed in the majority of rectal
cancers because of the low recurrence rates seen today without
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radiotherapy and the adverse effects of irradiation. The so-called
number needed to harm, in addition to the number needed to
treat, has become an important issue of discussion. The question to
be raised is whether it is necessary to lower the limited risk of
local recurrence even further (by approximately 60%) by adding
radiotherapy.
All trials that have tested chemotherapy versus surgery alone
were conducted in an era when surgery was far from optimal;
classic hemicolectomies were not always performed, and the
complete mesocolic excision technique was not used. In addition,
preoperative staging and postoperative pathology were suboptimal
according to present standards. The recurrence risks in patients
undergoing radical surgery (stage I to III disease) are thus likely
much lower today than they were when those trials were con-
ducted. Today, many centers can report survival ﬁgures clearly
better than those seen both with and without chemotherapy in the
older trials. In many cancer registries in Europe, patients with stage
I or II colon cancer have a 5-year survival rate greater than 90%; for
patients with stage III disease, this rate is approximately 80%14 (in
Swedish, Danish, and Dutch colorectal cancer registries). The
adjuvant chemotherapy administered according to recom-
mendations contributes to these results, and it is impossible to
know from modern series what the recurrence risk overall and in
each stage would be if no adjuvant chemotherapy were admin-
istered. A Nordic groupmade an attempt to ﬁnd out the recurrence
risk on the basis of a systematic literature review of modern
series, where the quality of care (including staging, surgery, and
pathology) would be reasonably high.26 It was not possible to
quantify the risk, but evidence indicated that the risk was con-
siderably lower than in the past, potentially lower than 10% to
15% in many groups of patients who would be considered for
adjuvant chemotherapy according to most guidelines (eg, those
with stage II disease with risk factors like pT4, , 12 nodes, poor
differentiation, or vascular and nerve invasion). There was a clear
lack of studies reporting recurrence ﬁgures with modern quality
of care.
Analogous to the experience in rectal cancer, the relative gains
from adjuvant chemotherapy using a ﬂuoropyrimidine alone in
colon cancer are likely (at least) to be the same as in the older trials.
In stage II disease, these gains range from 20% to 25% on the basis
of a Cochrane analysis and other systematic overviews.27 In stage
III disease, they are less well described but anticipated to be higher
(30% to 35%).28 Let us assume that the relative gains average 30%
in stage II and III disease combined. If 100 patients are treated with
adjuvant ﬂuoropyrimidine alone, and the absolute risk of recur-
rence is, for example, 20%, six patients will not experience
recurrence. Similarly, if the absolute risk of recurrence is 40%, 12
recurrences will be prevented in 100 treated patients. The addition
of oxaliplatin further reduces the risk by 18% to 20%, at least in
stage III disease and potentially also in stage II disease with risk
factors. Again, if 100 patients are treated, and the absolute risk
ﬁgures after surgery alone are as we have described (ie, 20% and
40%, respectively), an additional three (from 20 recurrences down
to 14 with a ﬂuoropyrimidine alone and down to approximately 11
with the combination) and six recurrences (from 40 down to 28
and approximately 22), respectively, will be prevented. Today, with
optimized staging, surgery, and pathology, if the absolute risks of
recurrence after surgery alone in the particular stages of disease are
not 20% and 40%but instead 10% and 20%, respectively, the absolute
gains are then three and six with a ﬂuoropyrimidine alone and are
further reduced by one to two with the addition of oxaliplatin per 100
treated patients. Today, the standard of care at most centers is ﬂu-
orouracil or capecitabine combined with oxaliplatin (eg, FOLFOX
[ﬂuorouracil, leucovorin, and oxaliplatin] or CAPOX [capecitabine
plus oxaliplatin] regimen) for all patients with stage III disease and
many patients with stage II disease, if risk factors for recurrence are
present. Because toxicity resulting from oxaliplatin treatment is not
negligible, with sometimes persistent neuropathy,29 many patients
with a low risk of recurrence will be harmed for little gain.
The present guidelines for adjuvant chemotherapy in stage II
colon cancer with and without risk factors and in stage III disease
are based on recurrence risks from the past. They are much lower
today, although we do not know precisely how much lower. The
reasons are mainly better surgery and better preoperative staging,
where many patients with metastatic disease have been “converted”
to synchronous from metachronous disease. Even if the relative
gains from administering adjuvant chemotherapy with or without
oxaliplatin are the same as those shown in the trials (with the
higher absolute risk ﬁgures), the absolute gains are less than they
were, and they may be too low to recommend therapy. It is not
realistic to conduct a new surgery-alone trial in the groups of
greatest interest (ie, those with anticipated recurrence risks of 10%
to 20%, or most patients with stage II and many with stage III
disease), as was done for radiotherapy in rectal cancer. Rather, it is
important to properly analyze risk ﬁgures in large unselected
populations where the quality of care is known and with an attempt
to control for the effects of adjuvant chemotherapy administered to
different proportions of patients. The number needed to treat is
high, and thus, many patients will unnecessarily be harmed. Today,
we must re-evaluate the need for administering routine adjuvant
chemotherapy to many patients with colon cancer when they are
receiving high-quality multidisciplinary care. Furthermore, a
much more differentiated stratiﬁcation than simply grouping
patients into stages II (with risk factors) and III (A, B, and C) is
required; some patients with stage III disease have a much lower
risk of recurrence than some patients with stage II. For example
(also an example of the amount of information needed in routine
care), we do not believe than an otherwise ﬁt 60-year-old patient,
who has undergone adequate staging and surgery, with left-sided
pT3b, N1 (1 positive, 28 sampled), no vessel (v-) or nerve (N-)
involvement, and low V malignancy grade colon cancer has a
sufﬁciently high recurrence risk to recommend adjuvant che-
motherapy, certainly not with oxaliplatin. If his or her preoperative
carcinoembryonic antigen level is very low or only moderately
elevated (eg, , 10) and normalizes postoperatively, the risk of
recurrence is likely less than 10%; the absolute beneﬁt of adjuvant
combination chemotherapy for this patient is low (four per 100
patients treated) compared with the morbidity associated with
receiving the two chemotherapy agents during 6months (or maybe
3 months in the future). Improving multidisciplinary care to meet
modern standards should lead to a reduction in the use of adjuvant
therapy in everyday practice.
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